Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort.

Abstract:

BACKGROUND:Surveillance colonoscopy is recommended for inflammatory bowel disease (IBD) patients with longstanding extensive colitis (LEC). AIMS:To assess modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in university French hospitals. METHODS:Among 910 eligible patients with more than a 7-year history of extensive colitis at CESAME enrolment, 685 patients completed a questionnaire on surveillance colonoscopy and 102 were excluded because of prior proctocolectomy. Finally, 583 patients provided information spanning a median period of 41months (IQR 38-43) between cohort enrolment and the end of follow-up. Details of the colonoscopic procedures and histological findings were obtained for 440 colonoscopies in 270 patients. RESULTS:Only 54% (n=312) of the patients with LEC had at least one surveillance colonoscopy during the study period, with marked variations across the nine participating centres (27% to 70%, P≤0.0001). Surveillance rate was significantly lower in Crohn's colitis than in ulcerative colitis (UC) (48% vs. 69%, P≤0.0001). Independent predictors of colonoscopic surveillance were male gender, UC IBD subtype, longer disease duration, previous history of CRC and disease management in a centre with large IBD population. Random biopsies, targeted biopsies and chromoendoscopy were performed during respectively 71%, 27 and 30% of surveillance colonoscopies. Two cases of high-grade dysplasia were detected in patients undergoing colonoscopic surveillance. Two advanced-stage CRC were diagnosed in patients who did not have colonosocopic surveillance. CONCLUSIONS:Colonoscopic surveillance rate is low in IBD patients with longstanding extensive colitis.

journal_name

Aliment Pharmacol Ther

authors

Vienne A,Simon T,Cosnes J,Baudry C,Bouhnik Y,Soulé JC,Chaussade S,Marteau P,Jian R,Delchier JC,Coffin B,Admane H,Carrat F,Drouet E,Beaugerie L

doi

10.1111/j.1365-2036.2011.04711.x

subject

Has Abstract

pub_date

2011-07-01 00:00:00

pages

188-95

issue

2

eissn

0269-2813

issn

1365-2036

journal_volume

34

pub_type

杂志文章
  • The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.

    abstract:BACKGROUND:Dexlansoprazole MR is a Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to extend the duration of acid suppression. AIM:To assess the 12-month safety of dexlansoprazole MR in patients with symptomatic gastro-oesophageal reflux disease (GERD). METHODS:In this ran...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2010.04519.x

    authors: Dabholkar AH,Han C,Paris MM,Perez MC,Atkinson SN,Peura DA

    更新日期:2011-02-01 00:00:00

  • Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs.

    abstract::Candidiasis of the oropharynx and oesophagus is one of the most common problems encountered in patients with HIV disease. Fluconazole is a bis-triazole antifungal agent with a long serum half-life. Sixteen anti-HIV positive patients (15 haemophiliacs and one blood transfusion recipient) with a clinical diagnosis of or...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1991.tb00021.x

    authors: Lim SG,Lee CA,Hales M,O'Doherty M,Winter M,Kernoff PB

    更新日期:1991-04-01 00:00:00

  • Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.

    abstract:BACKGROUND:Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. AIM:To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both d...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00806.x

    authors: Geus WP,Mathôt RA,Mulder PG,Lamers CB

    更新日期:2000-08-01 00:00:00

  • Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice.

    abstract:BACKGROUND:Duodenal villous atrophy (DVA) is a key diagnostic finding in coeliac disease (CD). However, the differential diagnosis for this finding is broad. AIM:To identify conditions causing noncoeliac enteropathy (NCE) with villous atrophy and methods to differentiate between CD and NCE in clinical practice. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04938.x

    authors: Pallav K,Leffler DA,Tariq S,Kabbani T,Hansen J,Peer A,Bhansali A,Najarian R,Kelly CP

    更新日期:2012-02-01 00:00:00

  • Effect of frequent dosing of an oral proton pump inhibitor on intragastric pH.

    abstract:BACKGROUND:Treatment with a continuous i.v. proton pump inhibitor is presumed to promote clot formation and stability by sustaining intragastric pH > or = 6. AIM:We postulated that very frequent oral dosing of proton pump inhibitors should simulate i.v. infusion and achieve similar pH control. METHODS:Twenty healthy ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02933.x

    authors: Pais SA,Nathwani RA,Dhar V,Nowain A,Laine L

    更新日期:2006-06-01 00:00:00

  • Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response.

    abstract:BACKGROUND:An impairment of cellular immune response may contribute to the persistency of hepatitis C virus infection. AIM:To analyse the Th1/Th2 cytokine profile in peripheral blood CD4(+) and CD8(+) T cells from patients with chronic hepatitis C (CHC) during treatment with pegylated interferon-alpha2a plus ribavirin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02954.x

    authors: Trapero-Marugán M,García-Buey L,Muñoz C,Quintana NE,Moreno-Monteagudo JA,Borque MJ,Fernández MJ,Salvanés FR,Medina J,Moreno-Otero R

    更新日期:2006-07-01 00:00:00

  • Susceptibility loci reported in genome-wide association studies are associated with Crohn's disease in Canadian children.

    abstract:BACKGROUND:Recent genome-wide association studies based on adult and paediatric populations have implicated >30 genes/loci as susceptibility loci for Crohn's disease (CD). AIMS:To investigate whether reported genes/loci were also associated with CD in Canadian children. DESIGN AND METHODS:A case-control design was im...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2010.04294.x

    authors: Amre DK,Mack DR,Morgan K,Israel D,Deslandres C,Seidman EG,Lambrette P,Costea I,Krupoves A,Fegury H,Dong J,Grimard G,Levy E

    更新日期:2010-06-01 00:00:00

  • Determinants of compliance with colonoscopy in patients with adenomatous colon polyps in a veteran population.

    abstract:AIM:To determine factors affecting compliance of a follow-up colonoscopy in patients with previously diagnosed adenomatous colon polyps. METHODS:A retrospective review was performed on patients with adenomatous polyps excised between January and December 1998. Twenty-nine clinical factors were assessed in patients gro...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03176.x

    authors: Siddiqui AA,Patel A,Huerta S

    更新日期:2006-12-01 00:00:00

  • Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome.

    abstract:AIM:To systematically review the literature evaluating hypnotherapy in the management of irritable bowel syndrome (IBS). METHODS:Electronic databases were searched (Cochrane Library, Medline, CINAHL, AMED, Embase, PsycINFO, CISCOM, TRIP and the Social Science Citation index), bibliographic references scanned and main ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.03028.x

    authors: Wilson S,Maddison T,Roberts L,Greenfield S,Singh S,Birmingham IBS Research Group.

    更新日期:2006-09-01 00:00:00

  • The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C.

    abstract:BACKGROUND:Intrahepatic non-hypervascular hypointense nodules (NHHNs) detected during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) have the potential to transition into typical hypervascular hepatocellular carcinoma (HCC). However, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15490

    authors: Toyoda H,Tada T,Yasuda S,Mizuno K,Sone Y,Kaneoka Y,Maeda A,Akita T,Tanaka J,Kumada T

    更新日期:2019-12-01 00:00:00

  • Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.

    abstract:BACKGROUND:Transplacental transfer of tumour necrosis factor-alpha (TNF-α) inhibitors has been shown in mothers receiving therapy for inflammatory bowel disease (IBD). AIM:To examine reports of adverse events of these medications in pregnancy. METHODS:Individual Safety Reports of adverse events (Jan 2003-June 2012) w...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12936

    authors: Deepak P,Stobaugh DJ

    更新日期:2014-11-01 00:00:00

  • Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.

    abstract:BACKGROUND:Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. AIM:To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. METHODS:Eleven patients (10%) diagnosed with fulminant...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02894.x

    authors: Miyake Y,Iwasaki Y,Terada R,Onishi T,Okamoto R,Sakai N,Sakaguchi K,Shiratori Y

    更新日期:2006-05-01 00:00:00

  • Effect of pepper and bismuth subsalicylate on gastric pain and surface hydrophobicity in the rat.

    abstract:BACKGROUND:The mechanism by which dietary pepper causes dyspepsia and epigastric pain is poorly understood, as is the ability of bismuth subsalicylate (BSS) to relieve these symptoms. AIM:To investigate the ability of black pepper, red pepper and BSS to affect gastric surface hydrophobicity and induce/relieve visceral...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1998.00327.x

    authors: Lichtenberger LM,Romero JJ,Carryl OR,Illich PA,Walters ET

    更新日期:1998-05-01 00:00:00

  • Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause.

    abstract:BACKGROUND:As there is considerable overlap between the fasting serum gastrin concentrations found in Zollinger-Ellison syndrome and various common conditions such as Helicobacter pylori infection and acid suppressing medication use, establishing the cause of hypergastrinaemia in individual cases can sometimes be diffi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.03976.x

    authors: Murugesan SV,Varro A,Pritchard DM

    更新日期:2009-05-15 00:00:00

  • Systematic review: the economic impact of irritable bowel syndrome.

    abstract:BACKGROUND:Although little mortality is associated with irritable bowel syndrome, curative therapy does not exist and thus the economic impact of this disorder may be considerable. METHODS:A systematic review of the literature was performed. Studies were included if their focus was irritable bowel syndrome, and direct...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.t01-1-01736.x

    authors: Inadomi JM,Fennerty MB,Bjorkman D

    更新日期:2003-10-01 00:00:00

  • Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.

    abstract:BACKGROUND:Alterations in serotonergic (5-HT) metabolism and/or intestinal integrity have been associated with irritable bowel syndrome (IBS). AIMS:To assess the effects of the precursor of 5-HT, 5-hydroxytryptophan (5-HTP), on mucosal 5-HT availability and intestinal integrity, and to assess potential differences bet...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.12842

    authors: Keszthelyi D,Troost FJ,Jonkers DM,van Eijk HM,Lindsey PJ,Dekker J,Buurman WA,Masclee AA

    更新日期:2014-08-01 00:00:00

  • Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia.

    abstract:BACKGROUND:Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are common functional disorders without defined pathology. Mast cells and eosinophils interact with T lymphocytes and may alter enteric nerve and smooth muscle function. AIM:To examine mast cell, eosinophil and intraepithelial lymphocyte populatio...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.03937.x

    authors: Walker MM,Talley NJ,Prabhakar M,Pennaneac'h CJ,Aro P,Ronkainen J,Storskrubb T,Harmsen WS,Zinsmeister AR,Agreus L

    更新日期:2009-04-01 00:00:00

  • Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

    abstract:AIM:: To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5-aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro-drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01408.x

    authors: Sandborn WJ,Hanauer SB

    更新日期:2003-01-01 00:00:00

  • Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret.

    abstract:BACKGROUND:In patients with primary sclerosing cholangitis follow-up magnetic resonance imaging (MRI) with magnetic resonance cholangiopancreatography (MRCP) is performed by many centres, particularly for the early detection of biliary malignancies and strictures. Clinically meaningful MRI-based definitions of primary ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14797

    authors: Zenouzi R,Liwinski T,Yamamura J,Weiler-Normann C,Sebode M,Keller S,Lohse AW,Schramm C,International PSC Study Group (IPSCSG).

    更新日期:2018-07-01 00:00:00

  • Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C.

    abstract:BACKGROUND:Interferon therapy has been shown to induce lipid abnormalities. AIM:We assessed the effects of interferon-beta on the lipoprotein profile and post-heparin lipase activities in 26 normolipaemic patients with chronic hepatitis C. METHODS:Interferon-beta was administered subcutaneously at doses of 6 x 106 U ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00792.x

    authors: Andrade RJ,García-Escaño MD,Valdivielso P,Alcántara R,Sánchez-Chaparro MA,González-Santos P

    更新日期:2000-07-01 00:00:00

  • Review article: Medical therapy for fistulizing Crohn's disease.

    abstract:BACKGROUND:Fistulae will develop in approximately one-third of patients with Crohn's disease. With an expected spontaneous healing rate of only 10%, fistulizing Crohn's disease requires a comprehensive strategy with a medical and possible surgical approach. AIM:To summarize the current literature evaluating various me...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.03126.x

    authors: Bressler B,Sands BE

    更新日期:2006-11-01 00:00:00

  • Octreotide (a somatostatin analogue) improves the quality of life in some patients with a short intestine.

    abstract::Six patients with short intestine (jejunal length 25-70 cm) on long-term parenteral nutrition, needing 4-5 L of intravenous fluid daily, were given octreotide (a somatostatin analogue, SMS 201-995) to investigate whether it would reduce beneficially their secretory diarrhoea (3.6-6.9 kg/day). They consumed the same di...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1989.tb00223.x

    authors: Nightingale JM,Walker ER,Burnham WR,Farthing MJ,Lennard-Jones JE

    更新日期:1989-08-01 00:00:00

  • Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a double-blind crossover study.

    abstract:BACKGROUND:Abnormal gall-bladder motility has been reported in diabetics. The objective was to evaluate the effect of chronic D2-dopamine receptor inhibition on gall-bladder emptying in diabetic patients. METHODS:Under double-blind placebo-controlled conditions and according to a crossover design, patients were random...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1995.tb00369.x

    authors: Mansi C,Savarino V,Vigneri S,Sciabà L,Perilli D,Mele MR,Celle G

    更新日期:1995-04-01 00:00:00

  • Pain and quality of life in patients with acute duodenal ulcer treated with ranitidine.

    abstract:BACKGROUND:The various components of pain and quality of life in duodenal ulcer patients receiving antisecretory drugs have not been studied to date. METHODS:Ninety-five patients with epigastric pain and duodenal ulcer at endoscopy completed this prospective, multicenter, open-study. All were treated with effervescent...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2036.1995.tb00402.x

    authors: Rampal P,Ruszniewski P,Boureau F,Richard A,Slama A

    更新日期:1995-08-01 00:00:00

  • Market share and costs of biologic therapies for inflammatory bowel disease in the USA.

    abstract:BACKGROUND:Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. AIM:To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. METHODS:The Truven MarketScan® Database was analysed for pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.14430

    authors: Yu H,MacIsaac D,Wong JJ,Sellers ZM,Wren AA,Bensen R,Kin C,Park KT

    更新日期:2018-02-01 00:00:00

  • Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    abstract:BACKGROUND:The best technique to estimate portal hypertension (PHT) is to measure the hepatic venous pressure gradient (HVPG), which is an invasive method. AIM:To assess the relationship between the Fibrotest (Biopredictive, Paris, France) and the presence and degree of PHT in patients with liver disease, and to deter...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2007.03378.x

    authors: Thabut D,Imbert-Bismut F,Cazals-Hatem D,Messous D,Muntenau M,Valla DC,Moreau R,Poynard T,Lebrec D

    更新日期:2007-08-01 00:00:00

  • An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively.

    abstract:BACKGROUND:The combination of omeprazole and amoxycillin has demonstrated effectiveness with very few side-effects in the treatment of H. pylori infection, however cure rates have varied widely. The present study addresses the question as to the extent to which the cure rate of H. pylori infection depends on the size o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1997.140316000.x

    authors: Miehlke S,Mannes GA,Lehn N,Hele C,Stolte M,Bayerdörffer E

    更新日期:1997-04-01 00:00:00

  • Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.

    abstract:AIM:To evaluate and compare two 1-week low-dose triple therapies based on lansoprazole, amoxycillin and a macrolide in eradicating Helicobacter pylori. METHODS:Seventy consecutive patients, suffering from dyspeptic symptoms with H. pylori infection, were randomly allocated to one of two treatment groups: (A) (LAC; n =...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1996.d01-533.x

    authors: Cammarota G,Tursi A,Papa A,Montalto M,Veneto G,Cuoco L,Fedeli G,Gasbarrini G

    更新日期:1996-12-01 00:00:00

  • Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

    abstract:BACKGROUND:The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation. AIM:To evaluate biochemical and virological relapse requiring retreatment in noncirrhotic HBeAg-negative CHB in patients who stopped treatment following a period of prolonged...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12908

    authors: Patwardhan VR,Sengupta N,Bonder A,Lau D,Afdhal NH

    更新日期:2014-10-01 00:00:00

  • Systematic review: macrophage activation syndrome in inflammatory bowel disease.

    abstract:BACKGROUND:Recently, there have been increasingly frequent reports on the occurrence of macrophage activation syndrome (MAS) in patients with inflammatory bowel disease (IBD). Clinically, MAS is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25. Mortality, even if ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12305

    authors: Fries W,Cottone M,Cascio A

    更新日期:2013-06-01 00:00:00